Status:

RECRUITING

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

Lead Sponsor:

University of Pennsylvania

Collaborating Sponsors:

Duke University

Conditions:

Cardiac Sarcoidosis

Eligibility:

All Genders

Brief Summary

This is a pilot mechanistic study of the diagnostic utility of sodium-glucose cotransporter-1/2 inhibition (SGLT1/2) on myocardial glucose suppression on FDG PET/CT. The investigators will test whethe...

Detailed Description

The purpose of this mechanistic pilot study is to evaluate the effect on myocardial glucose suppression, and therefore on image quality, with the addition of a brief course of an FDA approved SGLT1/2 ...

Eligibility Criteria

Inclusion

  • Adult patients, at least 18 years of age
  • No history of cardiovascular disease, including hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, cardiac surgery, arrhythmias per medical record review and/or self-report
  • No history of chronic liver or kidney disease per medical record review and/or self-report.
  • Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion

  • Females who are pregnant or breast-feeding will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test during the screening visit and prior to FDG injection.
  • Participants who are currently taking diuretics for any indication.
  • Participants with an eGFR level \<30 mL/min/1.73m2.
  • Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
  • Any other medical or psychological condition that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.

Key Trial Info

Start Date :

November 20 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2027

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06510894

Start Date

November 20 2024

End Date

December 31 2027

Last Update

January 7 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104